Lung Adenocarcinoma
Showing 1 - 25 of 78
Local and Peripheral Immune Responsive Landscape Induced by
Not yet recruiting
- Lung Adenocarcinoma
- Local Cryoablation
- (no location specified)
Oct 24, 2023
Lung Adenocarcinoma Trial in Shijiazhuang (Tislelizumab,Platinum)
Recruiting
- Lung Adenocarcinoma
-
Shijiazhuang, Hebei, ChinaThe Fourth Hospital of Hebei Medical University (Hebei Tumor Hos
Sep 24, 2023
Lung Adenocarcinoma, Lymph Node Metastasis Trial in Shanghai (Selective Lymph Node Dissection)
Recruiting
- Lung Adenocarcinoma
- Lymph Node Metastasis
- Selective Lymph Node Dissection
-
Shanghai, Please Select, ChinaChaoqiang Deng
Sep 4, 2023
Lung Adenocarcinoma, Frozen Section, Sublobar Resection Trial in Shanghai (Sublobar Resection)
Recruiting
- Lung Adenocarcinoma
- +2 more
- Sublobar Resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Sep 4, 2023
Tumor Microenvironment
Active, not recruiting
- Lung Adenocarcinoma
- (no location specified)
Aug 5, 2023
Novel Grading System of Resected Lung Adenocarcinoma
Recruiting
- Lung Adenocarcinoma
- +2 more
- Whole Slide Image based Deep Learning Signature
-
Zunyi, Guizhou, China
- +2 more
Jun 27, 2023
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma = 2cm
Recruiting
- Lung Adenocarcinoma
- Lobectomy with systemic lymph node dissection
- Segmentectomy with systemic lymph node dissection
-
Yangpu, Shanghai, ChinaShanghai Pulmonary Hospital
Apr 20, 2023
Intraoperative Frozen Section Pathology to Guide Surgical
Recruiting
- Lung Adenocarcinoma
- +2 more
- Surgical resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Mar 20, 2023
Intraoperative Frozen Section Pathology to Guide Surgical
Recruiting
- Lung Adenocarcinoma
- +2 more
- Surgical resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Mar 31, 2023
Intraoperative Frozen Section Pathology to Guide Surgical
Recruiting
- Lung Adenocarcinoma
- +2 more
- Surgical resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Mar 20, 2023
Novel Grading System of Clinical Stage I Lung Adenocarcinoma
Recruiting
- Lung Adenocarcinoma
- +2 more
- PET/CT-based Radiomics Signature
-
Zunyi, Guizhou, China
- +3 more
Feb 12, 2023
Segmentectomy, Lung Adenocarcinoma Trial (Segmentectomy)
Not yet recruiting
- Segmentectomy
- Lung Adenocarcinoma
- Segmentectomy
- (no location specified)
Jan 29, 2023
Lung Adenocarcinoma Trial in Los Angeles (drug, procedure, other)
Recruiting
- Lung Adenocarcinoma
-
Los Angeles, CaliforniaYesenia Calzada
Jan 27, 2023
Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)
Not yet recruiting
- Lung Adenocarcinoma
- +3 more
- Serplulimab and Bevacizumab injection
- (no location specified)
Dec 21, 2022
Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma Trial in Philadelphia (huCART-meso cells)
Recruiting
- Lung Adenocarcinoma
- +5 more
- huCART-meso cells
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Dec 1, 2022
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY159 Single agent dose level 1, PY159 Single
Recruiting
- Advanced Solid Tumor
- +7 more
- PY159 Single agent dose level 1
- +17 more
-
San Francisco, California
- +11 more
Nov 3, 2022
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)
Active, not recruiting
- MSI-H Colorectal Cancer
- +30 more
-
Badalona, Barcelona, Spain
- +9 more
Oct 24, 2022
Lung Adenocarcinoma, Lung Tumors Trial run by the NCI (osimertinib, LAT)
Completed
- Lung Adenocarcinoma
- Lung Neoplasms
- osimertinib
- LAT
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 17, 2022
Solid Tumors, Lung Adenocarcinoma, Osteosarcoma Trial in Tianjin (IBI188, GM-CSF, Cisplatin/Carboplatin)
Terminated
- Solid Tumors
- +2 more
- IBI188
- +5 more
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Oct 3, 2022
I3LUNG: Integrative Science, Intelligent Data Platform for
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
-
Chicago, Illinois
- +3 more
Sep 13, 2022
Lung Adenocarcinoma, Lung Large Cell Carcinoma, Resectable Lung Non-Small Cell Carcinoma Trial in Guam, Puerto Rico, United
Recruiting
- Lung Adenocarcinoma
- +12 more
- Carboplatin
- +12 more
-
Birmingham, Alabama
- +1612 more
Aug 23, 2022
ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and
Not yet recruiting
- ALK Gene Mutation
- +2 more
- Pembrolizumab Combined With Bevacizumab and Chemotherapy
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Jul 14, 2022